As of 2025-10-27, the EV/EBITDA ratio of Anika Therapeutics Inc (ANIK) is -30.51. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Anika's latest enterprise value is 91.18 mil USD. Anika's TTM EBITDA according to its financial statements is -2.99 mil USD. Dividing these 2 quantities gives us the above Anika EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 7.5x - 14.1x | 11.2x |
| Forward P/E multiples | 15.3x - 23.8x | 19.6x |
| Fair Price | 2.12 - 9.33 | 4.86 |
| Upside | -78.8% - -6.8% | -51.4% |
| Date | EV/EBITDA |
| 2025-10-17 | -26.46 |
| 2025-10-16 | -26.07 |
| 2025-10-15 | -26.07 |
| 2025-10-14 | -26.36 |
| 2025-10-13 | -26.12 |
| 2025-10-10 | -25.74 |
| 2025-10-09 | -27.67 |
| 2025-10-08 | -26.80 |
| 2025-10-07 | -26.07 |
| 2025-10-06 | -26.89 |
| 2025-10-03 | -25.98 |
| 2025-10-02 | -26.22 |
| 2025-10-01 | -26.85 |
| 2025-09-30 | -27.57 |
| 2025-09-29 | -26.32 |
| 2025-09-26 | -25.74 |
| 2025-09-25 | -25.64 |
| 2025-09-24 | -25.98 |
| 2025-09-23 | -26.22 |
| 2025-09-22 | -27.28 |
| 2025-09-19 | -25.16 |
| 2025-09-18 | -25.35 |
| 2025-09-17 | -24.00 |
| 2025-09-16 | -23.95 |
| 2025-09-15 | -23.95 |
| 2025-09-12 | -24.05 |
| 2025-09-11 | -23.85 |
| 2025-09-10 | -22.74 |
| 2025-09-09 | -24.34 |
| 2025-09-08 | -25.35 |
| 2025-09-05 | -25.35 |
| 2025-09-04 | -26.07 |
| 2025-09-03 | -25.69 |
| 2025-09-02 | -26.36 |
| 2025-08-29 | -27.47 |
| 2025-08-28 | -26.75 |
| 2025-08-27 | -26.51 |
| 2025-08-26 | -27.23 |
| 2025-08-25 | -26.27 |
| 2025-08-22 | -28.78 |
| 2025-08-21 | -25.88 |
| 2025-08-20 | -22.60 |
| 2025-08-19 | -23.66 |
| 2025-08-18 | -24.14 |
| 2025-08-15 | -24.82 |
| 2025-08-14 | -23.90 |
| 2025-08-13 | -26.03 |
| 2025-08-12 | -24.29 |
| 2025-08-11 | -21.83 |
| 2025-08-08 | -21.35 |